← Back to Search

Other

Lu AG06466 for Post-Traumatic Stress Disorder

Phase 1
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 12-13
Awards & highlights

Study Summary

This trial will study the effects of a new drug, Lu AG06466, on people with PTSD. The drug will be given in doses of 30mg.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 12-13
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 12-13 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Behavioural Measures During fMRI Tasks
Behavioural Measures During the Threat Processing Task
Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Card Guessing Task
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lu AG06466Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lu AG06466
2020
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

H. Lundbeck A/SLead Sponsor
326 Previous Clinical Trials
77,648 Total Patients Enrolled
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
188 Previous Clinical Trials
58,305 Total Patients Enrolled
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top